Clinical Developments for AXN-2510/IMM2510 in NSCLC Show Promise
March 4, 2025 - 12:22
Recent updates have highlighted significant advancements in the clinical development of AXN-2510/IMM2510, particularly in the treatment of relapsed and refractory non-small cell lung cancer (NSCLC) in China. ImmuneOnco is expected to release clinical data related to the monotherapy of AXN-2510/IMM2510 in the first half of 2025. This data is eagerly anticipated as it could provide valuable insights into the efficacy of the treatment.
Furthermore, the enrollment of patients with first-line NSCLC for a trial combining AXN-2510/IMM2510 with chemotherapy is projected to begin in the second quarter of 2025. Initial clinical results from this trial are expected to be available in the latter half of 2025, potentially paving the way for new treatment protocols.
In addition, plans are underway to initiate a U.S. clinical study of AXN-2510/IMM2510 in conjunction with chemotherapy for first-line NSCLC patients, with expectations for this to commence before the end of the year. These developments reflect a growing commitment to advancing therapies for NSCLC and improving patient outcomes.
MORE NEWS
May 25, 2026 - 18:00
Financial Exchanges & Data Stocks Q1 Teardown: Tradeweb Markets (NASDAQ:TW) Vs The RestThe close of earnings season offers a clear moment to look back and separate the winners from the laggards. For the financial exchanges and data sector, the first quarter of the year presented a...
May 25, 2026 - 11:24
Renter warning as Budget tax changes expected to fuel rise of corporate landlords: 'Quite surprised'Real estate professionals say they are `quite surprised` by how much the upcoming Budget appears to favor corporate landlords over individual investors. The expected tax changes are likely to...
May 24, 2026 - 21:19
A Look At Regions Financial (RF) Valuation After Recent Steady Share Price PerformanceRegions Financial (RF) has been catching the eye of investors lately, as its stock price holds steady after a series of mixed short-term moves. The shares recently closed at US$27.83, showing a...
May 24, 2026 - 12:36
How Investors Are Reacting To Veritone (VERI) Accounting Restatements, Lawsuits And Liquidity-Raising EffortsVeritone is drawing intense scrutiny from investors as the company navigates a storm of accounting restatements, shareholder lawsuits, and efforts to raise cash. The artificial intelligence firm...